Jinhe Biotechnology (002688.SZ) has issued an announcement stating that, in accordance with the provisions of the Regulations on the Administration of Veterinary Drugs and the Measures for Veterinary Drug Registration, following review by the Ministry of Agriculture and Rural Affairs, the inactivated lumpy skin disease vaccine (NMG strain) jointly developed by the company's subsidiary Jinhe Youben Biological Products Co., Ltd., Jinyu Baoling Biological Pharmaceutical Co., Ltd., and Luoyang Wopson Bioengineering Co., Ltd. has been approved as a new veterinary drug, and a New Veterinary Drug Registration Certificate has been issued.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments